Table 2.
Demographics, clinical and laboratory parameters of the cohort
| Patient no./sex/age in years | Disease duration, years | FVC at baseline | FVC at 1 year | DLCO at baseline | DLCO at 1 year | MRSS at baseline | MRSS at 1 year | Histological improvement | Skin B-cell depletion | Concurrent medications | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RTX | 1/F/47 | 6 | 85 | 88 | 67 | 78 | 14 | 10 | No | No | Pred, Bos |
| 2/M/72 | 5 | 55 | 62 | 40 | 49 | 8 | 2 | Yes | Yes | Pred, MMF | |
| 3/F/56 | 6 | 70 | 75 | 33 | 38 | 10 | 4 | Yes | No | Pred, Bos | |
| 4/M/39 | 13 | 30 | 35 | 14 | 27 | 29 | 21 | Yes | Yes | Pred, Bos, MMF | |
| 5/F/33 | 15 | 85 | 90 | 71 | 96 | 16 | 14 | No | No | Pred, MMF | |
| 6/F/56 | 7 | 90 | 97 | 67 | 67 | 12 | 4 | Yes | Yes | MMF | |
| 7/F/70 | 1 | 68 | 84 | 64 | 81 | 11 | 8 | NA | NA | – | |
| 8/F/50 | 2 | 62 | 74 | 62 | 60 | 8 | 4 | NA | NA | Pred | |
| Control | 9/F/60 | 9 | 72 | 75 | 61 | 59 | 13 | 14 | No | No | Pred, CYC |
| 10/F/73 | 15 | 57 | 52 | 26 | 16 | 12 | 10 | No | No | Pred | |
| 11/F/48 | 5 | 114 | 110 | 84 | 79 | 14 | 9 | NA | NA | Pred, Bos, MMF | |
| 12/F/47 | 4 | 91 | 85 | 66 | 60 | 12 | 9 | No | No | Bos, CYC | |
| 13/F/67 | 5 | 88 | 70 | 84 | 65 | 8 | 4 | NA | NA | Pred | |
| 14/F/52 | 2 | 94 | 98 | 71 | 82 | 10 | 12 | NA | NA | Pred, MMF |
Pred: low-dose prednisone; Bos: Bosentan; NA: not applicable.